Steffen Thirstrup

Steffen Thirstrup

Auto-generated profile, based on publicly available information

Steffen Thirstrup

European Medicines Agency, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PAPeter Arlett
Peter Arlett
DUDenise Umuhire
Denise Umuhire
PVPatrice Verpillat
Patrice Verpillat
PFPaolo Foggi
Paolo Foggi
ULUlla Wändel Liminga
Ulla Wändel Liminga
KBKarl Broich
Karl Broich

15 February 2024 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
HSHarriette G. C. Van Spall
Harriette G. C. Van Spall
ABArnaud Bastien
Arnaud Bastien
BGBernard Gersh
Bernard Gersh
BGBarry Greenberg
Barry Greenberg
RMReza Mohebi
Reza Mohebi
FZFaiez Zannad
Faiez Zannad

10 March 2026 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
LGLorenzo Guizzaro
Lorenzo Guizzaro
EBEwa Bałkowiec-Iskra
Ewa Bałkowiec-Iskra
MHMarion Haberkamp
Marion Haberkamp
PMPeter G.M. Mol
Peter G.M. Mol
AMAlexandre Moreau
Alexandre Moreau
BSBruno Sepodes
Bruno Sepodes
Alzheimer's disease (AD) remains the leading cause of dementia in Europe, with limited therapeutic options despite decades of research. Recent regulatory approvals of lecanemab and donanemab in the EU mark a significant milestone. Both antibodies, developed within the amyloid hypothesis, demonstrated statistically significant effects on cognitive and functional outcomes in patients with early AD, though the clinical meaningfulness of these effects remains debated. There are also important safety concerns, particularly amyloid-related imaging abnormalities (ARIA), which resulted in difficult benefit-risk assessments. The Personal View describes some of the lines of evidence considered by the European Medicines Agency in the assessment of efficacy of these medicines, and some of the measures to ensure their safe use. While these therapies do not halt disease progression, and have substantial risks, they represent a step toward more transformative treatments. Future research, including real-world evidence studies, should refine patient selection, optimise monitoring, and explore combination approaches and new targets to achieve improved outcomes.

23 February 2024 in Drug Safety
Verified
Journal Article
Open access
PDF file
ICIrina Caplanusi
Irina Caplanusi
ASAgnieszka Szmigiel
Agnieszka Szmigiel
MEMenno van der Elst
Menno van der Elst
MCMarie Louise Schougaard Christiansen
Marie Louise Schougaard Christiansen
STSteffen Thirstrup
Steffen Thirstrup
SSSabine Straus
Sabine Straus
The European Union (EU) regulatory network was at the forefront of the safety monitoring of COVID-19 vaccines during the pandemic. An unprecedented number of case reports of suspected adverse reactions after vaccination called for huge efforts for the assessment of this safety information, to ensure that any possible risks were detected and managed as early as possible, while ruling out coincidental but temporally related adverse health outcomes. We describe the role of the European Medicines Agency alongside the EU regulatory network in the safety monitoring of the COVID-19 vaccines, and provide an insight into challenges, particularities and outcomes of the scientific assessment and regulatory decisions in the complex, dynamic international environment of the pandemic. We discuss the flexible procedural tools that were used to ensure an expedited scientific assessment of safety issues, and subsequent updates of the product information (i.e., labelling) when available evidence (e.g., spontaneous reports, findings from observational studies and/or scientific literature) suggested that causal association is at least a reasonable possibility. The safety monitoring was accompanied by enhanced transparency measures, proactive communication, and easy access to information, which played a key role in public reassurance. The pandemic has been a powerful booster for worldwide collaboration, exchange of information and work-sharing. The safety monitoring of COVID-19 vaccines continues, and the lessons learned will be applied in future safety reviews, as well as future health emergencies.

11 January 2024 in Neuroscience Applied
Verified
Journal Article
Open access
DMDrummond E-Wen McCulloch
Drummond E-Wen McCulloch
MLMatthias E Liechti
Matthias E Liechti
KKKim Pc. Kuypers
Kim Pc. Kuypers
DNDavid Nutt
David Nutt
JLJohan Lundberg
Johan Lundberg
GKGitte Moos Knudsen
Gitte Moos Knudsen
Psychedelic drugs including psilocybin and LSD are undergoing clinical trials for a range of psychiatric and neurological conditions, and have particularly shown substantial promise in phase 2 studies of depression. In this article we outline key knowledge gaps that may be imperative for a successful implementation of psychedelic drugs as medicines as identified by members of the European College of Neuropsychopharmacology at the New Frontiers Meeting in Nice (2023). Key themes include pharmacokinetic and pharmacodynamic characterisation, comparisons between psychedelics, the relation between the duration of subjective effects and therapeutic outcomes, polypharmacology, and the impact of psychological support. We conclude with a perspective from the European Medicines Agency and Heath Technology Assessors on the most pressing requirements for medical implementation in Europe.

1 January 1997 in European Journal of Pharmacology
Verified
Journal Article
Closed access
STSteffen Thirstrup
Steffen Thirstrup
JNJens Erik Nielsen-Kudsk
Jens Erik Nielsen-Kudsk
SMSøren Mellemkjær
Søren Mellemkjær